Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Akorn Inc. Fell as Much as 16.4% Today

By Maxx Chatsko – Updated Oct 1, 2018 at 11:51AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors received new details explaining why Fresenius dropped its acquisition. They aren't good.

What happened

A bad 2018 keeps getting worse for specialty generic drug developer Akorn (AKRX). The company's shares fell over 16% today -- and are now down 61% year to date -- as a worrisome development got even worse.

Court documents made public late on Tuesday show that Fresenius (FMS -3.54%) dropped its acquisition of Akorn after uncovering evidence that the generic drug developer submitted fraudulent data to the U.S. Food and Drug Administration for at least six different drugs dating back to 2012.

That's a remarkable allegation -- and one that doesn't bode well for the smaller company's argument that the acquisition should proceed as originally intended.  

As of 3:18 p.m. EDT, the stock had settled to a 15.9% loss.

A man with his face on a desk and a sharply negative stock chart on the wall behind him.

Image source: Getty Images.

So what

The sequence of recent events makes a lot more sense now for investors. After originally agreeing to purchase Akorn in a $4.75 billion deal, Fresenius announced in February it was investigating "data integrity" issues uncovered during its due diligence into the acquisition. In April, it announced it was pulling out of the agreement to acquire the generic drug specialist. And now investors know why: "blatant fraud at the very top level of Akorn's executive team, stunning evidence of blatant and pervasive data integrity violations," according to a Reuters report on the court filing.

Akorn responded by saying that it fired an executive involved in the fraudulent scheme, while Fresenius said the executive is still being paid a salary of $250,000 as a consultant and stands to profit significantly from the merger. Additionally, the smaller company retorted that the six drugs alleged to have been submitted on fabricated information "either have never been marketed or are not currently being marketed and were never forecasted to form a material portion of Akorn's future earnings," again according to Reuters.

Shockingly, it doesn't appear that Akorn is denying that fraud took place. Rather, it's arguing that the acquisition should proceed because, hey, those drugs weren't that important anyway. If that's the culture of the company, then Fresenius and investors are better off avoiding the stock altogether.

Now what

It doesn't seem likely that a court would force Fresenius to proceed with its proposed acquisition. That leaves Akorn with a market cap of just $1.6 billion (far below the acquisition price) and a significant lack of trust with investors and Wall Street. It's tough to imagine a more toxic situation. Investors should avoid this stock at all costs.

Maxx Chatsko has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Akorn Stock Quote
Fresenius Medical Care Stock Quote
Fresenius Medical Care
$13.64 (-3.54%) $0.50

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.